| Most random gene expression signatures are significantly associated with breast cancer outcome D Venet, JE Dumont, V Detours PLoS computational biology 7 (10), e1002240, 2011 | 641 | 2011 |
| Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis Y Bareche, D Venet, M Ignatiadis, P Aftimos, M Piccart, F Rothe, ... Annals of oncology 29 (4), 895-902, 2018 | 369 | 2018 |
| Separation of samples into their constituents using gene expression data D Venet, F Pecasse, C Maenhaut, H Bersini Bioinformatics 17 (suppl_1), S279-S287, 2001 | 188 | 2001 |
| Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach Y Bareche, L Buisseret, T Gruosso, E Girard, D Venet, F Dupont, ... JNCI: Journal of the National Cancer Institute 112 (7), 708-719, 2020 | 173 | 2020 |
| RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial D Fumagalli, D Venet, M Ignatiadis, HA Azim, M Maetens, F Rothé, ... JAMA oncology 3 (2), 227-234, 2017 | 149 | 2017 |
| A statistical approach to central monitoring of data quality in clinical trials D Venet, E Doffagne, T Burzykowski, F Beckers, Y Tellier, ... Clinical Trials 9 (6), 705-713, 2012 | 134 | 2012 |
| Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative P Aftimos, M Oliveira, A Irrthum, D Fumagalli, C Sotiriou, EN Gal-Yam, ... Cancer discovery 11 (11), 2796-2811, 2021 | 133 | 2021 |
| Circulating tumor DNA in HER2-amplified breast cancer: a translational research substudy of the NeoALTTO phase III trial F Rothé, MJ Silva, D Venet, C Campbell, I Bradburry, G Rouas, ... Clinical cancer research 25 (12), 3581-3588, 2019 | 109 | 2019 |
| Absence of a specific radiation signature in post-Chernobyl thyroid cancers V Detours, S Wattel, D Venet, N Hutsebaut, T Bogdanova, MD Tronko, ... British journal of cancer 92 (8), 1545-1552, 2005 | 96 | 2005 |
| HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2 AB Hanker, JT Garrett, MV Estrada, PD Moore, PG Ericsson, JP Koch, ... Clinical Cancer Research 23 (15), 4323-4334, 2017 | 95 | 2017 |
| Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer CA Chang, J Jen, S Jiang, A Sayad, AS Mer, KR Brown, AML Nixon, ... Cancer discovery 12 (4), 1022-1045, 2022 | 79 | 2022 |
| Tumor-infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: a TRYPHAENA substudy M Ignatiadis, G Van den Eynden, S Roberto, M Fornili, Y Bareche, ... JNCI: Journal of the National Cancer Institute 111 (1), 69-77, 2019 | 76 | 2019 |
| Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells C Gómez-Aleza, B Nguyen, G Yoldi, M Ciscar, A Barranco, ... Nature communications 11 (1), 6335, 2020 | 75 | 2020 |
| Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer A Sonnenblick, S Brohée, D Fumagalli, D Vincent, D Venet, M Ignatiadis, ... BMC medicine 13, 1-10, 2015 | 65 | 2015 |
| Small amplified RNA‐SAGE: An alternative approach to study transcriptome from limiting amount of mRNA C Vilain, F Libert, D Venet, S Costagliola, G Vassart Nucleic acids research 31 (6), e24-e24, 2003 | 65 | 2003 |
| Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis WCG van Staveren, DW Solís, L Delys, D Venet, M Cappello, G Andry, ... Proceedings of the National Academy of Sciences 103 (2), 413-418, 2006 | 64 | 2006 |
| Pharmacological targeting of netrin-1 inhibits EMT in cancer J Lengrand, I Pastushenko, S Vanuytven, Y Song, D Venet, RM Sarate, ... Nature 620 (7973), 402-408, 2023 | 58 | 2023 |
| InSilico DB genomic datasets hub: an efficient starting point for analyzing genome-wide studies in GenePattern, Integrative Genomics Viewer, and R/Bioconductor A Coletta, C Molter, R Duqué, D Steenhoff, J Taminau, V De Schaetzen, ... Genome biology 13, 1-13, 2012 | 51 | 2012 |
| Linear mixed‐effects models for central statistical monitoring of multicenter clinical trials L Desmet, D Venet, E Doffagne, C Timmermans, T Burzykowski, ... Statistics in medicine 33 (30), 5265-5279, 2014 | 41 | 2014 |
| Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse F Cailleux, E Agostinetto, M Lambertini, F Rothé, HT Wu, M Balcioglu, ... JCO Precision Oncology 6, e2200148, 2022 | 39 | 2022 |
